Burns are one of the leading causes of hospitalization among children under four to five, according to scientists at Tyumen Medical University. In about 75% of cases, children suffer thermal injuries ...

The field of bovine immunology has made significant strides in understanding the biology and function of T cells, which are crucial players in shaping ...

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

DOR/ISL is currently at the pre-registration stage of development in the US and is expected to launch in this market in 2026, ...

Why can the human immune system often remember a vaccination for a whole lifetime? Researchers at ...

ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...

Gyala Therapeutics initiates phase I/IIa trial of a CAR-T cell therapy for acute leukaemias with limited treatment: Barcelona, Spain Wednesday, February 11, 2026, 18:00 Hrs [IST] ...

Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI responseDurable Clinical Observations ...

ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.

Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.